| Current Price | $7.51 | Mkt Cap | $268.9M |
|---|---|---|---|
| Open | $7.08 | P/E Ratio | -7.48 |
| Prev. Close | $7.51 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $7.08 - $7.55 | Volume | 117,335 |
| 52-Wk Range | $7.07 - $10.85 | Avg. Daily Vol. | 57,275 |
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients.
| Current Price | $7.51 | Mkt Cap | $268.9M |
|---|---|---|---|
| Open | $7.08 | P/E Ratio | -7.48 |
| Prev. Close | $7.51 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $7.08 - $7.55 | Volume | 117,335 |
| 52-Wk Range | $7.07 - $10.85 | Avg. Daily Vol. | 57,275 |
The best Bull and Bear pitches based on recency and number of recommendations.
Read the most recent pitches from players about FENC.
Find the members with the highest scoring picks in FENC.
See what the Wall Street professionals think, according to their public statements and filings.